Latest News
VistaGen Therapeutics Announces Common Stock Purchase Agreement for up to $10.25 Million
Read Press Release View All NewsLooking beyond current treatments for CNS diseases and disorders with high unmet need
VistaGen Therapeutics (NASDAQ: VTGN) is a clinical-stage biopharmaceutical company developing differentiated new generation medications for large and growing mental health and neurology markets where current treatments are inadequate to meet the needs of millions of patients worldwide.
Our CNS Pipeline